Aileron Therapeutics GAAP EPS of -$0.27 misses by $0.02 [Seeking Alpha]
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis [Yahoo! Finance]
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)